Introduction
Treatment of cystic fibrosis (CF) infections commonly involves iv therapy which is effective but stressful to the patient. It is expensive both in terms of cost of antibiotics and equipment and time missed from work. In children the trauma of frequent cannula insertions and removal from the family home should not be underestimated. Despite the current trend to try to give iv therapy at home, the majority of therapy is still given in the hospital. 1 A recent meta-analysis has shown that nebulized therapy is effective but it may cause an increase in resistance. 2 However, nebulized therapy requires special equipment, is time-consuming and is not well tolerated by some patients. Oral therapy, if effective, should have the additional benefit of good patient acceptance. Fluoroquinolones initially provided effective therapy with patient convenience but became limited with use because of rapidly increasing bacterial resistance. [3] [4] [5] [6] The aim of the present investigation was to determine the in-vitro effectiveness of an oral therapy consisting of a combination of ciprofloxacin with trimethoprim and
In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients The effect of triple therapy with ciprofloxacin, trimethoprim and either sulphadiazine or sulphamethoxazole on the MICs and development of resistance of three strains of Pseudomonas aeruginosa, two strains of Staphylococcus aureus and one of Burkholderia cepacia was compared with that of single or dual therapy with these agents using an agar dilution method. Ciprofloxacin MICs were 0.2-0.8 mg/L for the P. aeruginosa and S. aureus strains. For trimethoprim the MIC ranges were 64-128 and 0.25-1 mg/L for P. aeruginosa and S. aureus, respectively. For the sulphonamides the ranges were 64-2500 and 20-39 mg/L for P. aeruginosa and S. aureus, respectively. All combinations of agents were effective at lower concentrations than the single agents. The combination of ciprofloxacin, sulphonamide and trimethoprim showed enhanced activity against all test organisms. The highest ciprofloxacin concentration was one-tenth of the normally attainable serum concentration of 2.5 mg/L. Thus peak plasma concentrations of ≥8 MIC for ciprofloxacin against P. aeruginosa and S. aureus are theoretically achievable in the presence of clinically acceptable concentrations of trimethoprim and a sulphonamide, making the development of resistance less likely. The development of resistance, as shown by the proportional increase in MICs, was repressed by the triple regimen as compared with the development of resistance to agents used singly or in pairs. Killing curve determinations also demonstrated the advantage of the triple-agent therapy against all organisms tested: the combination of ciprofloxacin 0.5 mg/L, trimethoprim 1 mg/L and sulphadiazine 20 mg/L had an initial bactericidal effect against log-phase inocula of 10 6 cfu/mL of two clinical strains of P. aeruginosa and one clinical strain of S. aureus. The pseudomonas strains were reduced by 2-4 log cycles. Both recovered over 24 h but did not exceed the initial inoculum. The S. aureus was reduced to 10 2 cfu/mL in 4 h and did not recover over 24 h. A repeat dose of the triple therapy against the more resistant of the P. aeruginosa strains after 12 h also had a bactericidal effect. These data suggest the possibility of an effective exclusively oral therapy for the treatment of lung infections in cystic fibrosis patients. a sulphonamide (sulphamethoxazole or sulphadiazine) against organisms commonly implicated in infections in CF patients. Trimethoprim and sulphonamides affect cell envelope synthesis and resultant cell ultrastructure, thereby enhancing the uptake and subsequent activity of a number of antibacterials including ciprofloxacin. [7] [8] [9] In addition, taking account of the work of Blaser et al., 10 who showed that resistance to enoxacin (and ciprofloxacin) is much less likely to occur when peak concentrations of 8 MIC against specific bacteria are used, the potential of using trimethoprim and sulphadiazine or sulphamethoxazole to lower the MIC of ciprofloxacin against bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus was also investigated. This could provide a mechanism for obtaining peak plasma concentrations of ciprofloxacin more than eight times their initial MICs against specific bacteria and thus reduce the possibility or rate of development of bacterial resistance.
Materials and methods
Two strains of P. aeruginosa (B and C) and one of S. aureus (D) were isolated from CF patients. P. aeruginosa NCTC 6750, S. aureus NCTC 10788 and Burkholderia cepacia NCTC 10743 were obtained from the National Collection of Type Cultures, Public Health Laboratory Service, Colindale Avenue, London, UK. Iso-sensitest broth and agar (Oxoid, Basingstoke, UK) were the culture media. Ciprofloxacin, trimethoprim, sulphadiazine and sulphamethoxazole were all obtained from Sigma (Poole, UK).
MICs
MICs were determined by an agar dilution method. Organisms from an 18 h Iso-sensitest broth culture were diluted in Iso-sensitest broth, and 5 L of this dilution was spotted in quadruplicate with a Brand multipoint inoculator on to Iso-sensitest agar containing serial two-fold dilutions of either ciprofloxacin, sulphadiazine, sulphamethoxazole or trimethoprim. Agar plates were incubated at 37°C for 24 h and the MIC was taken as the lowest concentration that inhibited visible growth in all four spots. After determining the MIC for each antibacterial singly against each of the test strains, combination MICs were determined. The microdilution viable counting method was employed to determine the size of inoculum for each set of MIC determinations.
In-vitro development of resistance
Ciprofloxacin-, trimethoprim-and sulphonamide-resistant mutants were selected according to the method used by Doss et al. 5 Each of the study strains was inoculated into Iso-sensitest broth containing ciprofloxacin, trimethoprim, sulphadiazine and sulphamethoxazole alone or in combination at concentrations equivalent to 0.5 MIC. After 24 h, 0.1 mL aliquots were subcultured on to Iso-sensitest agar containing either no antibacterial or antibacterials, singly or in combination, at concentrations equivalent to 1, 2 or 5 MIC for each strain. Mutants detected on the plates following incubation at 37°C for 24 h were subcultured into antibacterial-free Iso-sensitest broth. After ten serial passages the MICs of the antibacterial agents against the mutants were assessed in order to determine whether any resistance was stable or not. A viable count was carried out using the microdilution method to determine the size of inoculum so as to ensure a valid comparison between initial and final MIC determinations. Proportional MIC increases were calculated as final MIC/initial MIC.
Killing curve determinations
One millilitre of an 18 h culture of bacteria was used to inoculate 99 mL of Iso-sensitest broth. The culture was then incubated at 37°C with shaking at 100 oscillations/ min for 4 h. Ten millilitre quantities of these log-phase cultures were then used to inoculate 250 mL conical flasks containing 90 mL of prewarmed Iso-sensitest broth plus either ciprofloxacin, sulphadiazine or trimethoprim alone or in combination. The antimicrobial concentrations tested for all three clinical samples either alone or in combination were ciprofloxacin 0.5 mg/L, trimethoprim 1 mg/L and sulphadiazine 20 mg/L. A conical flask containing 90 mL of Iso-sensitest broth without any antibacterial was used as the control. Viable counts were determined 0, 0.5, 1, 2, 3, 4, 5 and 24 h after exposure to the antibacterials. The effect of a repeat dosing of antibacterials alone and in combination at 12 h against one of the P. aeruginosa isolates was also investigated.
Results

MICs
The MICs of ciprofloxacin, trimethoprim, sulphadiazine and sulphamethoxazole singly and in combination against P. aeruginosa B and C, S. aureus D, P. aeruginosa NCTC 6750, S. aureus NCTC 10788 and B. cepacia NCTC 10743 are given in Tables I, II and III, respectively. Triple combinations were effective at lower concentrations than the single agents. The concentration of trimethoprim in combination with ciprofloxacin against all strains of P. aeruginosa was greater than normal peak plasma concentrations. The sulphonamides in combination with ciprofloxacin indicated greater mutual enhancement of activity and were well within clinically attainable levels for all test organisms except in the case of sulphadiazine with P. aeruginosa B and NCTC 6750. The combination of ciprofloxacin, sulphonamide and trimethoprim showed enhanced activity against all test organisms. In the case of P. aeruginosa C the reduction in concentration of ciprofloxacin was negligible but the sulphonamide and trimethoprim concentrations were reduced by a factor of around 20 and 400 respectively. All concentrations were well within attainable peak plasma concentrations. The highest concentration of ciprofloxacin was one-tenth of the normally attainable clinical level of 2.5 mg/L.
Development of resistance
The development of resistance after exposure to increased concentrations of antibacterial singly and in various combinations against the clinical isolates of two strains of P. aeruginosa and one strain of S. aureus is shown as a proportional increase of the original MICs in Table IV . The proportional increase for the combinations of three antibacterials remained at the initial low levels for two strains and was doubled for the third strain. The proportional increase in MICs with the three antibacterial combinations against each of the bacterial strains was mostly lower than for the combinations of two antibacterials. This was similar for the single agents except for ciprofloxacin and sulphadiazine alone against P. aeruginosa B and C respectively which remained at the original MICs. However, this MIC for ciprofloxacin was three to six times greater than in the combination of ciprofloxacin, trimethoprim and sulphamethoxazole or sulphadiazine, respectively.
Killing curve determinations
The effects of clinically attainable concentrations of the single and combined antibacterials on the viability of each of the clinical isolates are given in Figures 1-4 . The effect on log-phase cells of the two P. aeruginosa strains was very 
The concentration of sulphadiazine was too high to determine. similar. Trimethoprim and sulphadiazine alone and in combination had no observable effect on cell viability. Ciprofloxacin alone and in all combinations had a marked initial bactericidal effect; for P. aeruginosa B (Figure 1 ) the cfu/mL were reduced by approximately 2 log cycles in a period of 1 h while for P. aeruginosa C (Figure 2 ) the reduction was 3 log cycles over 2 h. All cultures indicated a slow recovery of growth but at 24 h there was an observable differentiation in the growth rate between cultures having different treatments. This was most marked for ciprofloxacin alone against the culture of P. aeruginosa C (Figure 2 ). This culture was the only original treated culture to reach a cell concentration greater than the original inoculum. The effect against log-phase S. aureus ( Figure 3 ) was very different. Only the sulphadiazine alone was ineffective. Ciprofloxacin and trimethoprim alone and ciprofloxacin plus sulphadiazine were initially bactericidal, reducing the cfu/mL by 1.5 log cycles and maintaining this reduction to 8 h. After 24 h all these cultures had recovered to approximately the same count as the control culture. In marked contrast, the combination of all three agents, and dual combinations of ciprofloxacin trimethoprim and trimethoprim sulphadiazine reduced the cfu/mL by 3 log cycles over 4-5 h. These cultures did not recover to countable numbers over the 24 h period. The triple combination had a slightly more rapid action than the other two combinations.
The effect of a repeat dose after 12 h with the various antibacterial treatments is seen in Figure 4 . The most resistant of the P. aeruginosa strains was used for this assessment. The results indicate that repeat treatment with the regimens which were effective initially produced an additional bactericidal effect and maintained culture levels at approximately 10 4 cfu/mL over the remainder of the 24 h period.
Discussion
The results of the MIC determinations (Tables I, II and III) indicate that enhanced activity was obtained from the use of clinically achievable concentrations of ciprofloxacin in combination with trimethoprim and either sulpha- diazine or sulphamethoxazole against all the test bacteria. This includes B. cepacia, which was not a clinical isolate but is often responsible for lung infections in CF patients. P. aeruginosa C was a mucoid strain but was sensitive to the ciprofloxacin combinations. Further work would be necessary to determine the activity of the ciprofloxacin combinations against mucoid strains in general. The enhancement of ciprofloxacin activity is not of the same magnitude as the synergy obtained with trimethoprim and sulphonamides against a range of bacterial species. Nevertheless it is relevant in relation to the treatment of lung infections in CF patients. This can be deduced by relating our results to the findings of Blaser et al., 10 who showed that bacterial resistance for specific organisms is unlikely to develop to ciprofloxacin if concentrations of 8 MIC are used. In the results reported here for the three-agent regimen, peak plasma ciprofloxacin concentrations of 8 MIC for the test organisms could theoretically be obtained in the presence of clinically acceptable concentrations of trimethoprim and a sulphonamide.
The results of resistance determinations (Table IV) indicate that the three antibacterials used in combination have, overall, a repressive effect on the development of resistance by P. aeruginosa B and C and S. aureus D compared with the development of resistance to individual agents and combinations of two agents.
The killing curve determinations (Figures 1-4) taken as a whole indicate the advantage of the triple antibacterial regimen against all organisms tested. This confirms previous work in our laboratory [7] [8] [9] 11, 12 and provides the possibility for an effective exclusively oral therapy for the treatment of CF infections. It is hoped that that this potential can be explored in the clinical situation as an initial treatment for lung infections in CF patients. 
